NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) (NVS) - Price, trends, fundamentals and chart - Passport to Wall Street

NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) (NYSE: NVS)

Overview

current price

$111.40

$111.40

change

0.00 | 0.00%

0.00 | 0.00%

Yesterday's Close

111.40

open

0.00

volume

0.00 M

30d. avg volume.

2.46 M

1 day

0.00 - 0.00

52 weeks

92.35 - 120.92

p/e

18.82

beta

0.5471

market cap

235.32 B

dividend yield

0.00%

Industry

-

News and Commentary

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could... Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective f...

Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Dr... Swiss pharma giant Novartis AG (

Market Update: S&P 500, Nasdaq Retreat, Dow Climbs 200 Points on Stock Rotation The S&P 500 Index and Nasdaq Composite slipped lower on Wednesday as investors rotated out of semiconductor names and into more rate sensitive names. This, in turn, lead the Dow...

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stol... U.S. drug wholesaler Cencora Inc (

Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease Researchers at Alphabet Inc's (

Market Update: Dow Climbs 260 Points on Strong Second-Quarter Earnings Stocks climbed higher on Tuesday as the second-quarter earnings season delighted investors, helping to build on gains from the prior session. The Dow Jones Industrial Average ros...

Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Mar... After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-declining trend.

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administrati...

Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs Novartis AG (NVS

From Years to Months: How AI is Shaping the Landscape of Clinical Trials Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significan...

StockTwits

StockTwits